| Literature DB >> 21054244 |
Martin Schleef1, Markus Blaesen, Marco Schmeer, Ruth Baier, Corinne Marie, George Dickson, Daniel Scherman.
Abstract
After some decades of research, development and first clinical approaches to use DNA vectors in gene therapy, cell therapy and DNA vaccination, the requirements for the pharmaceutical manufacturing of gene vectors has improved significantly step by step. Even the expression level and specificity of non viral DNA vectors were significantly modified and followed the success of viral vectors. The strict separation of "viral" and "non viral" gene transfer are historic borders between scientist and we will show that both fields together are able to allow the next step towards successful prevention and therapy. Here we summarize the features of producing and modifying these non-viral gene vectors to ensure the required quality to modify cells and to treat human and animals.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21054244 DOI: 10.2174/156652310793797711
Source DB: PubMed Journal: Curr Gene Ther ISSN: 1566-5232 Impact factor: 4.391